Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. ...
Medpace Holdings, Inc. (NASDAQ: MEDP), founded in Cincinnati, Ohio in 1992 by Dr. August J. Troendle, is a leading global clinical contract research organization (CRO). The company offers comprehensive, full-service drug and medical device development solutions, spanning the entire product lifecycle from early-phase clinical trials to post-market surveillance. Medpace's integrated services include clinical trial design and management, central laboratory services, bioanalytical laboratory testing, ECG and imaging core labs, regulatory affairs support, data management, biostatistics, pharmacovigilance, and medical writing. The company operates in over 40 countries with approximately 6,200 employees, serving clients across North America, Europe, and Asia. Medpace is known for its scientifically-driven approach, emphasizing regulatory and therapeutic expertise. Financially, the company has demonstrated strong performance with a market capitalization of about $16.5 billion as of the latest data, and robust revenue generation, though it does not pay dividends. The company's profitability metrics such as return on equity and profit margins are strong, indicating efficient operations. Medpace's business model focuses on providing outsourced clinical development services, reducing the cost and time of bringing new therapies to market for its clients. Its leadership has been stable with its founder at the helm, contributing to a focused and experienced management team. The company's future outlook involves continued expansion in emerging markets and leveraging advanced technologies to enhance clinical trial efficiency. Overall, Medpace plays a critical role in the healthcare ecosystem by enabling the development of innovative medical products that improve patient lives globally.
